December 9 - 12, 2018
Hilton San Diego Bayfront
San Diego, California, USA
Abstract submission deadline: Thursday, September 27
Advance registration deadline: Friday, November 2
Conference CochairsFrank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CaliforniaGideon Bollag, Plexxikon, Inc., Berkeley, CaliforniaKaren M. Cichowski, Harvard Medical School, Brigham & Women's Hospital, Boston, MassachusettsShiva Malek, Genentech, Inc., South San Francisco, California
Mutations in RAS genes, KRAS in particular, are present in 30% of all cancers. As a result of key therapeutic advances as well as improvements in areas of basic research due to updated technologies, the last 5 years have witnessed an invigoration in the field. Therapeutic discoveries directed at targeting KRAS, as well as effectors in artificial membranes becoming more accessible, have helped KRAS re-emerge as a “druggable” target.
This conference will focus on potentially druggable aspects of KRAS biology, including emergent areas such as systems approaches and immunotherapy. The conference will leverage the substantial gains in recent years in the understanding of proximal targeting of KRAS to provide a comprehensive and in-depth forum, and will include field leaders in all aspects of KRAS biology to allow for direct engagement between industry and academia.
Professional Educational Grants
Continuing Medical Education Activity
AMA PRA Category 1 CreditsTM available